-
Watch: Navigating Steroid Choices – Understanding the Process, Pathways, and Policies (Webinar Recording)
Last week, PPMD was joined by Kathy Mathews, MD (Neurologist), Christina Trout, RN, MSN (Clinic […]
-
‘Favorable risk-benefit profile’ seen for DMD treatment SRP-5051: Trial
SRP-5051 is able to increase the production of dystrophin protein in people with Duchenne muscular […]
-
Sarepta Therapeutics Announces Positive Data for Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Sarepta Therapeutics reported positive data for SRP-5051, their next-generation exon skipping agent designed for individuals amenable […]
-
Sarepta Therapeutics Reports Positive Data from Part B of MOMENTUM Study of SRP-5051
Sarepta Therapeutics, Inc. today announced positive data from Part B of SRP-5051-201, the MOMENTUM study. […]
-
PPMD 2023 Duchenne Early Care Meeting Report Published: Enhancing Support in Early Diagnosis
Last year, PPMD hosted a Duchenne Early Care meeting as part of the 2023 Duchenne […]
-
Duchenne Added to Minnesota’s Newborn Screening Panel
PPMD is excited to announce another significant milestone: Minnesota has officially approved the addition of […]
-
Sometimes living with Duchenne is simply too hard
I love to read, but finding time to sit down with a good book can […]
-
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) in Europe
PPMD is disappointed to learn that the European Medicines Agency (EMA)’s Committee for Medicinal Products […]
-
Coping with seasonal affective disorder and FSHD as best I can
The symptoms of my facioscapulohumeral muscular dystrophy (FSHD) make staying positive a daily challenge. Many […]
-
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
As an early funder of PepGen, we are pleased to share that PenGen has dosed […]
